Tuesday, May 02, 2017 12:36:29 PM
____________________________________________________
Is Pfizer really weighing a BMS buy? Clues from Q1's earnings call say it just may be
by Carly Helfand | May 2, 2017 11:35am
Pfizer CEO Ian Read told investors on Tuesday that he thinks the company has the ability to swallow a large deal if the right opportunity arises.
Is Pfizer thinking of buying Bristol-Myers Squibb, as the rumors go? CEO Ian Read hinted at the possibility on Tuesday's first-quarter earnings call—but investors shouldn’t expect any immediate action, he cautioned.
As Read told shareholders on the call, “we … believe we have the ability, should the opportunity arise and should the value be there, to do a large deal.”
He noted, though, that “certain large companies have significant, almost binary risks … which could immediately alter their values,” which is one reason the company won’t be rushing into anything.
Bristol-Myers, whose status in the immuno-oncology field was compromised last year by a flopped first-line immonotherapy trial in non-small cell lung cancer, certainly fits that bill. Its lung cancer hopes are now resting on a combo of PD-1 med Opdivo and a CTLA-4 drug—an approach that’s not shared by Merck's rival Keytruda and Roche's Tecentriq, which are going after checkpoint inhibitor/chemo pairings.
With that in mind, snatching up BMS wouldn’t make a lot of sense for Pfizer “until more clarity is gained on how the battle will shake out between ‘CTLA4 combo’ and ‘chemo combo,’" Bernstein analyst Tim Anderson has written to clients, noting that “having the value of the target change materially for the worse could make management look bad.”
Bristol-Myers’ struggles first ignited merger rumors early this year, and the ever-deal-seeking Pfizer was quick to see its name pop up as a potential buyer. One reason? Despite its partnership with Merck KGaA on avelumab—which recently picked up its first approval, a Merkel cell carcinoma nod, under the brand name Bavencio—analysts say the New York pharma is not necessarily a lock to be a leader in the so-called second wave of immuno-oncology drugmakers.
Read, though, insisted on Tuesday that Pfizer is “committed” to the partnership and remains “focused on developing avelumab”—though he also acknowledged that backing out of the deal wouldn't be a megadealbreaker.
“I don’t think that any type of breakup fee would be material compared to the size of a large deal,” he said, suggesting a potential BMS buy would trump walking out on Merck.
Questions surrounding the combo approach aren’t the only factor holding up Pfizer’s dealmaking activity, though. Read listed uncertainty around U.S. tax reform and even the French election as reasons to stay put for now—a stark contrast to the company’s last earnings call, on which the Pfizer chief insisted it would “continue to do BD where we see value for our shareholders” instead of taking a “dramatic pause” to wait and see “what the tax code’s going to do.”
The way Goldman Sachs analyst Jami Rubin sees things, that business development is all the more important in light of Pfizer’s first-quarter performance, which saw some key meds fall short of estimates. In a note to clients, she pointed in particular to Xtandi, whose $131 million in sales is “clearly weak given [Pfizer] paid $14 billion for this asset,” and Xeljanz, which came in $38 million behind consensus, writing that the misses raised “concerns about Pfizer’s ability to grown in the absence of M&A in our view.”
Pfizer, for its part, attributed part of the revenue miss to a selling period slightly shorter than last year’s, which it said took $300 million off its $12.79 billion revenue tally. And despite the time crunch, it was able to best forecasts with breast cancer-fighter Ibrance, which raked in $679 million to edge Wall Street’s $672 million prediction.
All eyes are on that drug now that Novartis is out with rival Kisqali, which undercut Ibrance on price. Pfizer’s innovative health president Albert Bourla, though, reminded investors on the call that the company had successfully “managed … price competition in the past, and we will do it in the future.”
Meanwhile, the company managed a beat on the earnings front thanks to lower expenses and a gain on divestments, reporting per-share profits of 69 cents that topped the 67-cent consensus estimate. It also reaffirmed its 2017 guidance, and “and we continue to maintain the numbers are well within reach,” Barclays analyst Geoff Meacham wrote in an investor note.
________________________________________________________
http://www.fiercepharma.com/pharma/pfizer-really-weighing-a-bms-buy-clues-from-q1-s-earnings-call-say-it-just-may-be
BMY
Recent BMY News
- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis • Business Wire • 09/18/2024 10:59:00 AM
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma • Business Wire • 09/15/2024 12:55:00 PM
- Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 • Business Wire • 09/12/2024 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/10/2024 09:45:00 PM
- Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms • Business Wire • 09/09/2024 10:59:00 AM
- Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research • Business Wire • 09/06/2024 11:00:00 AM
- Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) • Business Wire • 09/01/2024 07:33:00 AM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 08/27/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024 • Business Wire • 08/26/2024 10:59:00 AM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma • Business Wire • 08/21/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma • Business Wire • 08/19/2024 10:59:00 AM
- Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots • IH Market News • 07/30/2024 10:00:51 AM
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 • Business Wire • 07/26/2024 10:59:00 AM
- U.S. Index Futures Point to Higher Open, Oil Prices Down • IH Market News • 07/26/2024 10:08:50 AM
- Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates • IH Market News • 07/26/2024 09:57:38 AM
- Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma • Business Wire • 07/19/2024 10:59:00 AM
- Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day • Business Wire • 07/08/2024 10:59:00 AM
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 06/21/2024 11:30:00 PM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab • Business Wire • 06/21/2024 10:59:00 AM
- Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024 • Business Wire • 06/20/2024 10:59:00 AM
- Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors • Business Wire • 06/18/2024 08:16:00 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 06/18/2024 10:59:00 AM
- U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors • Business Wire • 06/13/2024 08:46:00 PM
- Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial • Business Wire • 06/04/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM